On Medical Treatments & Products Archives

Statement on Behalf of Members of the Patient, Consumer, and Public Health Coalition at the FDA Advisory Committee on Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and Informed Consent

March 26, 2019. NCHR testified at the FDA advisory committee meeting on Breast Implants on improving informed consent procedures for informing patients on risks of BIA-ALCL

NCHR Testimony to FDA on NeuroAD Therapy System in Alzheimer’s Patients

March 21, 2019. NCHR testifies at an FDA Neurological Devices Advisory Committee regarding NeuroAD, a proposed treatment for Alzheimer’s dementia.

NCHR Comments on USPSTF’s on Pancreatic Cancer Screening

March 4, 2019. We support the USPSTF’s draft recommendation against screening for pancreatic cancer in asymptomatic adults because screening asymptomatic adults does not improve patient outcomes and poses its own risks.

NCHR Testimony to FDA on Selinexor for Relapsed Refractory Multiple Myeloma

February 26, 2019. Selinexor has serious risks, and we don’t know if it works. Tell FDA to wait until the randomized trial is analyzed to make a decision.

Is FDA Doing Enough to Make Sure Sunscreens are Safe?

February 22, 2019. NCHR supports the FDA’s issued guidance regarding sunscreen sold over-the-counter that contains ingredients not thoroughly studied.